Capivasertib in combination with Faslodex granted Priority Review in the US for patients with advanced HR-positive breast cancer
Decision based on CAPItello-291 Phase III trial results which showed the combination reduced the risk of disease progression or death by 40% vs. Faslodex alone.Potential first-in-class AKT inhibitor being reviewed under Project Orbis.AstraZeneca’s New Drug Application (NDA) for capivasertib in combination with Faslodex (fulvestrant) has been accepted and granted Priority Review in the US for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer following recurrence or